JNJ 87562761
Alternative Names: JNJ-2761; JNJ-87562761Latest Information Update: 05 Mar 2026
At a glance
- Originator Janssen Research & Development
- Class Antibodies; Antineoplastics; Immunotherapies
- Mechanism of Action Antibody-dependent cell cytotoxicity; Apoptosis stimulants; Natural killer cell stimulants; Phagocyte stimulants
-
Orphan Drug Status
No
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- Phase I Multiple myeloma
Most Recent Events
- 06 Dec 2025 Pharmacodynamics data from preclinical studies in Multiple myeloma presented at the 67th American Society of Hematology Annual Meeting and Exposition (ASH-Hem-2025)
- 18 Dec 2024 Phase-I clinical trials in Multiple myeloma (Second-line therapy or greater) in Canada (unspecified route) (NCT06604715)
- 18 Dec 2024 Phase-I clinical trials in Multiple myeloma (Second-line therapy or greater) in Spain (unspecified route) (NCT06604715)